Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma-Reference-Cited by-同舟云学术

Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma

Published:2018-05-08 Issue:5 Volume:13 Page:e0196780
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Yoshida Takashi,Ri Masaki^ORCID,Kinoshita Shiori,Narita Tomoko,Totani Haruhito,Ashour Reham,Ito Asahi,Kusumoto Shigeru,Ishida Takashi,Komatsu Hirokazu,Iida Shinsuke

Funder

Grant-in-Aids for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology

National Cancer Center Research and Development Fund

Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and development, AMED

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference35 articles.

1. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone;S Jagannath;Haematologica,2006

2. Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis;M Leiba;British Journal of Haematology,2014

3. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial;MV Mateos;Journal of clinical oncology: official journal of the American Society of Clinical Oncology,2010

4. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications;N Mitsiades;Blood,2003

5. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial;BG Durie;Lancet (London, England),2017

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunophenotypic expression profile of multiple myeloma cases at a tertiary hospital in Nairobi Kenya;Frontiers in Medicine;2023-05-12

2. Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation;BMC Cancer;2022-12-23

3. Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide‐treated myeloma patients;Hematological Oncology;2022-12-02

4. The impact of CD56 expression in smoldering myeloma patients on early progression;Hematological Oncology;2022-12

5. Activating transcription factor 4 regulates hypoxia inducible factor 1α in chronic hypoxia in pancreatic cancer cells;Oncology Reports;2022-11-23